Ivarmacitinib at both 4 mg and 8 mg doses was found to be efficacious in treating alopecia areata in a phase 3 trial.
Alvotech and Dr. Reddy’s announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...
High dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent ... We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for ...
Soon-to-be medical school graduates received 877 more primary care position offers in the 2025 Main Residency Match compared with the previous year, according to the National Resident Matching ...
adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, mavrilimumab, tofacitinib and upadacitinib), either with or without concomitant csDMARD therapy. No matching studies in treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback